UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 51

Sortiert nach

Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer

PloS one, 2021-07, Vol.16 (7), p.e0254765-e0254765

2021

Volltextzugriff (PDF)

Modeling the subcutaneous pharmacokinetics of antibodies co‐administered with rHuPH20

Clinical and translational science, 2024-04, Vol.17 (4), p.e13788-n/a

2024

Volltextzugriff (PDF)

The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies

Journal of controlled release, 2024-10, Vol.374, p.369-383

2024

Volltextzugriff (PDF)

Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery

Expert opinion on drug delivery, 2021-11, Vol.18 (11), p.1673-1685

2021

Volltextzugriff (PDF)

Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration

The AAPS journal, 2022-10, Vol.24 (6), p.110-110, Article 110

2022

Volltextzugriff (PDF)

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers

Current therapeutic research, 2020-01, Vol.93, p.100604, Article 100604

2020

Volltextzugriff (PDF)

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson’s disease

Neurobiology of disease, 2007-07, Vol.27 (1), p.67-76

2007

Volltextzugriff (PDF)

Engineering of Tooth-Supporting Structures by Delivery of PDGF Gene Therapy Vectors

Molecular therapy, 2004-04, Vol.9 (4), p.519-526

2004

Volltextzugriff (PDF)

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

The AAPS journal, 2015-09, Vol.17 (5), p.1144-1156

2015

Volltextzugriff (PDF)

Tolerability and Pharmacokinetic Properties of Ondansetron Administered Subcutaneously With Recombinant Human Hyaluronidase in Minipigs and Healthy Volunteers

Clinical therapeutics, 2014-02, Vol.36 (2), p.211-224

2014

Volltextzugriff (PDF)

Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

The AAPS journal, 2015-11, Vol.17 (6), p.1523-1524

2015

Volltextzugriff (PDF)

Matrix immobilization enhances the tissue repair activity of growth factor gene therapy vectors

Human gene therapy, 2001-05, Vol.12 (7), p.783-798

2001

Volltextzugriff (PDF)

PH20 is not expressed in murine CNS and oligodendrocyte precursor cells

Annals of clinical and translational neurology, 2017-03, Vol.4 (3), p.191-211

2017

Volltextzugriff (PDF)

Plasma hyaluronan is a predictive marker for pegvorhyaluronidase alfa (PEGPH20; PVHA) response in a phase II study of pancreatic ductal adenocarcinoma (PDAC)

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.404-404

2019

Volltextzugriff (PDF)

Baseline plasma HA in PDA versus healthy subjects and effects of PEGPH20 on plasma HA in PDA subjects treated with GEM/NAB

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e15699-e15699

2016

Volltextzugriff (PDF)

Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease

Neurosurgery, 2009-04, Vol.64 (4), p.602-613

2009

Volltextzugriff (PDF)

Abstract 3375: Phase 1 pharmacodyamic activity of multiple-dose PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3375-3375

2013

Volltextzugriff (PDF)

Adenovirus Encoding Human Platelet-Derived Growth Factor-B Delivered in Collagen Exhibits Safety, Biodistribution, and Immunogenicity Profiles Favorable for Clinical Use

Molecular therapy, 2004-05, Vol.9 (5), p.699-711

2004

Volltextzugriff (PDF)

Abstract 2672: Phase 1 pharmacokinetics (PK) & pharmacodynamics (PD) of PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2672-2672

2012

Volltextzugriff (PDF)

Abstract 5392: Synergistic anti-tumor effects of pegylated recombinant human hyaluronidase (PEGPH20) with Gemcitabine in subcutaneous pancreatic cancer xenograft models

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.5392-5392

2010

Volltextzugriff (PDF)

Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism : Evidence for reduced toxicity and enhanced antitumor activity in mice

Cancer research (Chicago, Ill.), 1999-06, Vol.59 (11), p.2608-2614

1999

Volltextzugriff (PDF)

Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors

Human gene therapy, 2000, Vol.11 (1), p.191-204

2000

Volltextzugriff (PDF)

EXPRESSION, BIOACTIVITY, AND SAFETY 1 YEAR AFTER ADENO-ASSOCIATED VIRAL VECTOR TYPE 2-MEDIATED DELIVERY OF NEURTURIN TO THE MONKEY NIGROSTRIATAL SYSTEM SUPPORT CERE-120 FOR PARKINSON'S DISEASE. Commentaries

Neurosurgery, 2009, Vol.64 (4), p.602-613

2009

Volltextzugriff (PDF)

947. Effects of Natural Pre-Existing Humoral Immunity to AAV on Administration of AAV2-NTN to the Brain of Non-Human Primates

Molecular therapy, 2005-05, Vol.11 (S1), p.S366-S366

2005

Volltextzugriff (PDF)

539. Biodistribution and Safety Profile of CERE-110 (AAV2-NGF) Delivered to the Rodent Brain

Molecular therapy, 2004-05, Vol.9 (S1), p.S203-S204

2004

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(51)

Sprache

Englisch
(51)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer

Modeling the subcutaneous pharmacokinetics of antibodies co‐administered with rHuPH20

The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies

Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery

Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson’s disease

Engineering of Tooth-Supporting Structures by Delivery of PDGF Gene Therapy Vectors

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

Tolerability and Pharmacokinetic Properties of Ondansetron Administered Subcutaneously With Recombinant Human Hyaluronidase in Minipigs and Healthy Volunteers

Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

Matrix immobilization enhances the tissue repair activity of growth factor gene therapy vectors

PH20 is not expressed in murine CNS and oligodendrocyte precursor cells

Plasma hyaluronan is a predictive marker for pegvorhyaluronidase alfa (PEGPH20; PVHA) response in a phase II study of pancreatic ductal adenocarcinoma (PDAC)

Baseline plasma HA in PDA versus healthy subjects and effects of PEGPH20 on plasma HA in PDA subjects treated with GEM/NAB

Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease

Abstract 3375: Phase 1 pharmacodyamic activity of multiple-dose PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors

Adenovirus Encoding Human Platelet-Derived Growth Factor-B Delivered in Collagen Exhibits Safety, Biodistribution, and Immunogenicity Profiles Favorable for Clinical Use

Abstract 2672: Phase 1 pharmacokinetics (PK) & pharmacodynamics (PD) of PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors

Abstract 5392: Synergistic anti-tumor effects of pegylated recombinant human hyaluronidase (PEGPH20) with Gemcitabine in subcutaneous pancreatic cancer xenograft models

Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism : Evidence for reduced toxicity and enhanced antitumor activity in mice

Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors

EXPRESSION, BIOACTIVITY, AND SAFETY 1 YEAR AFTER ADENO-ASSOCIATED VIRAL VECTOR TYPE 2-MEDIATED DELIVERY OF NEURTURIN TO THE MONKEY NIGROSTRIATAL SYSTEM SUPPORT CERE-120 FOR PARKINSON'S DISEASE. Commentaries

947. Effects of Natural Pre-Existing Humoral Immunity to AAV on Administration of AAV2-NTN to the Brain of Non-Human Primates

539. Biodistribution and Safety Profile of CERE-110 (AAV2-NGF) Delivered to the Rodent Brain

Suchergebnisse filtern